Pages that link to "Q36395455"

The following pages link to Interaction of pergolide with central dopaminergic receptors (Q36395455):

Displaying 48 items.

• Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives (Q33714121) (← links)
• Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease (Q33985023) (← links)
• Development of a methodology to measure the effect of ergot alkaloids on forestomach motility using real-time wireless telemetry (Q34330261) (← links)
• The effect of a single oral dose of pergolide on intraocular pressure and pupil diameter (Q34397719) (← links)
• Reduction in size of prolactin-secreting tumours in men treated with pergolide (Q34762352) (← links)
• Sodium ion modulates D2 receptor characteristics of dopamine agonist and antagonist binding sites in striatum and retina (Q36303022) (← links)
• Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins (Q36797984) (← links)
• Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease (Q37917111) (← links)
• Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients (Q38444112) (← links)
• D-1 and D-2 agonists in Parkinson's disease (Q39483648) (← links)
• Stimulation of pre- and postsynaptic dopamine receptors by an ergoline and by a partial ergoline (Q39565877) (← links)
• Clinical pharmacokinetics of anti-parkinsonian drugs (Q39673262) (← links)
• Multiple dopamine receptors and behavior (Q40090864) (← links)
• The pharmacology of Parkinson's disease: basic aspects and recent advances (Q40214837) (← links)
• Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications (Q40247201) (← links)
• Antagonism by domperidone of the ocular hypotensive effect of pergolide (Q42005639) (← links)
• Dopamine agonists and Parkinson's disease (Q42240480) (← links)
• Chronic cocaine treatment does not alter rat striatal D2 autoreceptor sensitivity to pergolide (Q44889879) (← links)
• Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes (Q48108519) (← links)
• Affinity shifts induced by cations do not reliably predict the agonistic or antagonistic nature of ligands at brain dopamine receptors (Q48190509) (← links)
• Complete conversion of brain D2 dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide (Q48485041) (← links)
• Solubilization and characterization of striatal dopamine receptors (Q48673811) (← links)
• The selectivity of some ergot derivatives for α1 and α2-adrenoceptors of rat cerebral cortex (Q48762262) (← links)
• Muscarinic receptors on dopamine terminals in the cat caudate nucleus: Neuromodulation of [3H]dopamine release in vitro by endogenous acetylcholine (Q48895480) (← links)
• Effects of clozapine in a selective muscarinic bioassay and on single cells of the rat hippocampus (Q48924444) (← links)
• Depletion of epinephrine in rat hypothalamus by a dopamine agonist, pergolide (Q48963705) (← links)
• Pergolide therapy in Parkinson's disease (Q49092700) (← links)
• The regulation of striatal DOPA synthesis by α2-adrenoreceptors (Q49129533) (← links)
• Longterm pergolide treatment of acromegaly (Q51644963) (← links)
• Discordant responses of prolactinoma to two different dopamine agonists. (Q54429944) (← links)
• Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat (Q60050281) (← links)
• Suppression of REM rebound by Pergolide (Q64762934) (← links)
• Postsynaptic bimodal effect of sulpiride on locomotor activity induced by pergolide in catecholamine-depleted mice (Q68352827) (← links)
• Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats (Q69863619) (← links)
• The characterization of the dopaminergic profile of EMD 23,448, and indolyl-3-butylamine: selective actions on presynaptic and supersensitive postsynaptic DA receptor populations (Q69909150) (← links)
• Treatment of Parkinson's disease with pergolide: a double-blind study (Q70216121) (← links)
• Dopamine receptor mediated inhibition by pergolide of electrically-evoked 3H-dopamine release from striatal slices of cat and rat: Slight effect of ascorbate (Q70919851) (← links)
• Effect of a stereospecific D2-dopamine agonist on acetylcholine concentration in corpus striatum of rat brain (Q71147343) (← links)
• Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion (Q71344986) (← links)
• Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists (Q72553001) (← links)
• LY141865, a D2-dopamine agonist, increases acetylcholine concentration in rat corpus striatum (Q72555688) (← links)
• Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites (Q72577410) (← links)
• Vasodilator effects of dopaminomimetics in the perfused rat kidney (Q72681257) (← links)
• A risk-benefit assessment of drugs used in the management of Parkinson's disease (Q72768879) (← links)
• Dopaminergic inhibition of cardiac sympathetic nerve function by pergolide (Q72923018) (← links)
• Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole (Q73458382) (← links)
• Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration (Q74126307) (← links)
• Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane (Q96302945) (← links)